Beta Drugs profitability ratios

·UnclassifiedChart ›
Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY25Mar 2025
Returns
18.8%18.8%21.5%
8.9%8.9%9.7%
16.2%16.2%18.6%
9.1%16.7%—
Margins
20.8%19.7%20.6%
15.2%15.2%17.1%
—−15.9%—
15.8%14.1%15.7%
12.0%10.8%11.7%
−4.2%−4.2%−1.5%
Additional
23.9%23.7%25.5%
18.8%18.8%21.5%
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

BETA₹1,849.70

Beta Drugs Limited

· Unclassified
₹ CrorePeersTHEJOMACPOWERSAKARSERVOTECHMcap ₹1,875 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Returns
Return on Common Equity21.5218.7818.78
Return on Assets9.728.908.90
Return on Capital Employed18.6216.2316.23
Return on Invested Capital—16.679.07
Margins
EBITDA Margin20.5919.6720.78
Operating Margin17.1415.2115.21
Incremental Operating Margin—-15.87—
Pretax Margin15.7214.1315.78
Net Income Margin11.7110.7812.01
FCF Margin-1.45-4.21-4.21
Additional
Effective Tax Rate25.5423.7423.94
Sustainable Growth Rate21.5218.7818.78
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.